NIUM
Esch-sur-alzette
About NIUM
The gut microbiome plays a crucial role in health and disease, yet existing models for studying microbiome interactions are slow, expensive, and unreliable. Current in-vitro systems lack scalability and physiological accuracy, while clinical trials are costly and impractical for early-stage R&D. This bottleneck limits innovation in food, nutrition, and pharma, preventing companies from efficiently testing and developing microbiome-targeted products. NIUM solves this with the first fully automated, scalable gut-microbiome-on-a-chip platform, enabling cost-effective, high-throughput testing at lower cost with superior reproducibility.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $523.0K
- Funding stage: Seed
- Last round: Seed (Sep 2024)
- Website: nium.bio
Industries & Categories
Biotechnology, Food Processing, Nutrition
Social Profiles
Canonical: https://fsome.com/organization/nium-151211 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.